Axsome Therapeutics(MX:AXSM)
MX$1,519.000.00 (0.00%)
MX:AXSM
Axsome Therapeutics stock forecast
MX$1,519.00
At close:0.00 (0.00%)
Axsome Therapeutics (AXSM) Stock Forecast & Price Target
1 Followers
AXSM Analyst Ratings
Strong Buy
18Buy1Hold0Sell
Based on 19 analysts giving stock ratings to Axsome Therapeutics in the past 3 months
AXSM Stock 12 Month Forecast
Average Price Target
MXN 4,838.02â–²(218.50% Upside)Based on 19 Wall Street analysts offering 12 month price targets for Axsome Therapeutics in the last 3 months. The average price target is MXN 4,838.02 with a high forecast of MXN 5,759.08 and a low forecast of MXN 2,507.99. The average price target represents a 218.50% change from the last price of MXN 1,519.00.
Past 12 Months12 Month ForecastJan2026Oct2026
HighMXN 5.76K
AverageMXN 4.84K
LowMXN 2.51K
Highest Price TargetHighestMXN 5,759.08Average Price TargetMXN 4,838.02Lowest Price TargetLowestMXN 2,507.99
Detailed List of Analyst Forecasts​
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Ram Selvaraju | H.C. Wainwright | MXN 5,387.53 | buy | 254.68%Upside | Reiterated | 11/09/26 | ||
| Graig Suvannavejh | Mizuho Securities | MXN 5,276.06→MXN 5,053.13 | buy | 232.66%Upside | Reiterated | 11/04/26 | ||
| Ashwani Verma | UBS | MXN 4,755.89→MXN 4,440.07 | buy | 192.30%Upside | Assigned | 11/03/26 | ||
| Sean Laaman | Morgan Stanley | MXN 4,588.69→MXN 4,625.85 | hold | 204.53%Upside | Assigned | 11/03/26 | ||
| Brian Skorney | Robert W. Baird | MXN 4,570.11→MXN 4,087.09 | buy | 169.06%Upside | Reiterated | 11/03/26 | ||
| Benjamin Burnett | Wells Fargo | MXN 4,755.89 | buy | 213.09%Upside | Assigned | 11/03/26 | ||
| Yatin Suneja | Guggenheim | MXN 5,108.87→MXN 4,644.42 | buy | 205.76%Upside | Reiterated | 11/03/26 | ||
 Unknown AnalystNot Ranked | B. Riley Securities | MXN 5,573.31 | buy | 266.91%Upside | Initiated | 11/03/26 | ||
| David Hoang | Deutsche Bank | MXN 4,960.24→MXN 4,551.53 | buy | 199.64%Upside | Reiterated | 11/03/26 | ||
| David Amsellem | Piper Sandler | MXN 4,421.49→MXN 4,365.76 | buy | 187.41%Upside | Reiterated | 11/02/26 | ||
| Andrew Tsai | Jefferies | MXN 7,059.52→MXN 5,666.20 | buy | 273.02%Upside | Assigned | 11/02/26 | ||
| Joseph Thome | TD Cowen | MXN 5,851.97→MXN 2,507.99 | buy | 65.11%Upside | Reiterated | 11/02/26 | ||
| Jason Gerberry | Bank of America Securities | MXN 5,127.44→MXN 4,904.51 | buy | 222.88%Upside | Reiterated | 11/02/26 | ||
| Leonid Timashev | RBC Capital | MXN 5,480.42→MXN 5,071.71 | buy | 233.88%Upside | Assigned | 11/02/26 | ||
| Pete Stavropoulos | Cantor Fitzgerald | MXN 5,053.13 | buy | 232.66%Upside | Reiterated | 11/02/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Ram SelvarajuH.C. Wainwright | BuyReiteratedMXN 5,387.53 | 11/09/26 | 254.68%Upside | ||
| Graig SuvannavejhMizuho Securities | BuyReiteratedMXN 5,276.06→MXN 5,053.13 | 11/04/26 | 232.66%Upside | ||
| Ashwani VermaUBS | BuyAssignedMXN 4,755.89→MXN 4,440.07 | 11/03/26 | 192.30%Upside | ||
| Sean LaamanMorgan Stanley | HoldAssignedMXN 4,588.69→MXN 4,625.85 | 11/03/26 | 204.53%Upside | ||
| Brian SkorneyRobert W. Baird | BuyReiteratedMXN 4,570.11→MXN 4,087.09 | 11/03/26 | 169.06%Upside | ||
| Benjamin BurnettWells Fargo | BuyAssignedMXN 4,755.89 | 11/03/26 | 213.09%Upside | ||
| Yatin SunejaGuggenheim | BuyReiteratedMXN 5,108.87→MXN 4,644.42 | 11/03/26 | 205.76%Upside | ||
| Unknown AnalystB. Riley SecuritiesNot Ranked | BuyInitiatedMXN 5,573.31 | 11/03/26 | 266.91%Upside | ||
| David HoangDeutsche Bank | BuyReiteratedMXN 4,960.24→MXN 4,551.53 | 11/03/26 | 199.64%Upside | ||
| David AmsellemPiper Sandler | BuyReiteratedMXN 4,421.49→MXN 4,365.76 | 11/02/26 | 187.41%Upside | ||
| Andrew TsaiJefferies | BuyAssignedMXN 7,059.52→MXN 5,666.20 | 11/02/26 | 273.02%Upside | ||
| Joseph ThomeTD Cowen | BuyReiteratedMXN 5,851.97→MXN 2,507.99 | 11/02/26 | 65.11%Upside | ||
| Jason GerberryBank of America Securities | BuyReiteratedMXN 5,127.44→MXN 4,904.51 | 11/02/26 | 222.88%Upside | ||
| Leonid TimashevRBC Capital | BuyAssignedMXN 5,480.42→MXN 5,071.71 | 11/02/26 | 233.88%Upside | ||
| Pete StavropoulosCantor Fitzgerald | BuyReiteratedMXN 5,053.13 | 11/02/26 | 232.66%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Axsome Therapeutics
3 Months
Success Rate18/29 ratings generated profit
62%
Average Return
+16.67%
Copying Joseph Thome's trades and holding each position for 3 Months would result in 62.07% of your transactions generating a profit, with an average return of +16.67% per trade.
1 Year
Success Rate21/29 ratings generated profit
72%
Average Return
+45.14%
Copying Joseph Thome's trades and holding each position for 1 Year would result in 72.41% of your transactions generating a profit, with an average return of +45.14% per trade.
2 Years
Success Rate31/44 ratings generated profit
70%
Average Return
+45.04%
Copying Graig Suvannavejh's trades and holding each position for 2 Years would result in 70.45% of your transactions generating a profit, with an average return of +45.04% per trade.
AXSM Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 11 | 24 |
| Buy | 35 | 29 | 33 | 25 | 13 |
| Hold | 2 | 1 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 38 | 32 | 37 | 38 | 39 |
In the current month, AXSM has received 37 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. AXSM average Analyst price target in the past 3 months is 4,838.02.
AXSM Financial Forecast
HighMXN 11.90
ConsensusMXN -0.89
LowMXN -10.12
AXSM Earnings Forecast
Next quarter’s earnings estimate for AXSM is -MXN 0.89 with a range of -MXN 10.12 to MXN 11.90. The previous quarter’s EPS was -MXN 4.65. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighMXN 6.08B
ConsensusMXN 5.28B
LowMXN 4.96B
AXSM Sales Forecast
Next quarter’s sales forecast for AXSM is MXN 5.28B with a range of MXN 4.96B to MXN 6.08B. The previous quarter’s sales results were MXN 4.83B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
AXSM Stock Forecast FAQ
What is MX:AXSM’s average 12-month price target, according to analysts?
Based on analyst ratings, Axsome Therapeutics’s 12-month average price target is Mex$4,838.02.
What is MX:AXSM’s upside potential, based on the analysts’ average price target?
Axsome Therapeutics has 218.50% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Axsome Therapeutics a Buy, Sell or Hold?
Axsome Therapeutics has a consensus rating of Strong Buy, which is based on 18 buy ratings, 1 hold ratings and 0 sell ratings.
What is Axsome Therapeutics’s share price target?
The average share price target for Axsome Therapeutics is Mex$4,838.02. This is based on 19 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is Mex$5,759.08, and the lowest forecast is Mex$2,507.99. The average share price target represents a 218.50% increase from the current price of Mex$1,519.
What do analysts say about Axsome Therapeutics?
Axsome Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Street analysts.
How can I buy shares of Axsome Therapeutics?
To buy shares of MX:AXSM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
